Nanobody-mediated CAR-T cell platforms directed against either PD-L1 or the fibronectin splice variant EIIIB exhibited significant antitumor efficacy and improved tumor immune infiltration in immunocompetent murine models of solid malignancies. The gene discussed is CD274; the disease is neoplasm.